News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Comprehensive clinical development programs being initiated for each investigational candidate
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Subscribe To Our Newsletter & Stay Updated
